We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Microsoft, Adaptive Biotech Collaborate to Fight COVID-19
Read MoreHide Full Article
Microsoft (MSFT - Free Report) and Adaptive Biotechnologies (ADPT - Free Report) recently extended partnership in a bid to aid public health officials and researchers to access and track data pertaining to COVID-19 patient immune responses.
The dataset is aimed at enabling health care practitioners to develop diagnostic blood test through which virus can detected accurately despite people being asymptomatic. Moreover, the dataset can be leveraged to analyze and enhance the order of treatment for newly diagnosed COVID-19 patients.
The open source dataset will be deployed on Microsoft’s cloud computing platform, Azure. Microsoft’s robust Azure Artificial Intelligence (AI) and machine learning (ML) capabilities will complement Adaptive’s strength in “immunosequencing” technology.
Increasing adoption of Azure to support healthcare workloads provide the cloud platform with immense exposure in the domain, which is a positive. Robust adoption of the company’s offerings is instilling confidence in the stock.
Notably, shares of the company have returned 16.7% in the past year, compared with the industry’s rally of 1.7%.
Microsoft & Healthcare Players Team Up
The researchers and public-health organizations will be able to access the dataset of the research inferences and other findings for free, via an open-access portal, which will be made available in the days ahead.
The process involves collection of blood samples from COVID-19 patients who eventually recovered, with an aim to accelerate medical fraternity’s efforts to develop a vaccine for the pandemic.
Laboratory Corporation of America Holdings’ (LH - Free Report) Covance Drug Development arm, and mobile phlebotomy service will be utilized by Adaptive to collect anonymous blood samples, beginning April, and map immune response data.
Providence and Illumina, which is engaged in DNA-sequencing technology, have also joined the initiative. Notably, an initial clinical collaborator happens to be the first U.S. COVID-19 patient, treated by Providence’s hospital near Seattle.
The companies intend to scale the open data initiative globally to enrich the database, which is expected to eventually improve the inference as the sample broadens.
Wrapping Up
Microsoft’s latest initiative is a testament to the company’s growing focus on expanding presence in the multi-trillion healthcare sector with innovative solutions. Moreover, Microsoft’s ongoing healthcare initiatives in partnership with Nuance, Providence St. Joseph Health, Walgreens Boots Alliance, and UCLA, remain noteworthy.
For instance, Apple has unveiled a new COVID-19 section in Apple News in a bid to offer latest verified reports from trusted sources. Further, the company has taken strong measures to scrutinize the data provides by COVID-19 related apps in AppStore.
Microsoft’s expanded partnership with Adaptive is expected to aid the broader medical fraternity and the global ecosystem to advance initiatives to contain the COVID-19 spread and find a cure.
Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, SherazMian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
Image: Bigstock
Microsoft, Adaptive Biotech Collaborate to Fight COVID-19
Microsoft (MSFT - Free Report) and Adaptive Biotechnologies (ADPT - Free Report) recently extended partnership in a bid to aid public health officials and researchers to access and track data pertaining to COVID-19 patient immune responses.
.jpg)
The dataset is aimed at enabling health care practitioners to develop diagnostic blood test through which virus can detected accurately despite people being asymptomatic. Moreover, the dataset can be leveraged to analyze and enhance the order of treatment for newly diagnosed COVID-19 patients.
The open source dataset will be deployed on Microsoft’s cloud computing platform, Azure. Microsoft’s robust Azure Artificial Intelligence (AI) and machine learning (ML) capabilities will complement Adaptive’s strength in “immunosequencing” technology.
Increasing adoption of Azure to support healthcare workloads provide the cloud platform with immense exposure in the domain, which is a positive. Robust adoption of the company’s offerings is instilling confidence in the stock.
Notably, shares of the company have returned 16.7% in the past year, compared with the industry’s rally of 1.7%.
Microsoft & Healthcare Players Team Up
The researchers and public-health organizations will be able to access the dataset of the research inferences and other findings for free, via an open-access portal, which will be made available in the days ahead.
The process involves collection of blood samples from COVID-19 patients who eventually recovered, with an aim to accelerate medical fraternity’s efforts to develop a vaccine for the pandemic.
Laboratory Corporation of America Holdings’ (LH - Free Report) Covance Drug Development arm, and mobile phlebotomy service will be utilized by Adaptive to collect anonymous blood samples, beginning April, and map immune response data.
Providence and Illumina, which is engaged in DNA-sequencing technology, have also joined the initiative. Notably, an initial clinical collaborator happens to be the first U.S. COVID-19 patient, treated by Providence’s hospital near Seattle.
The companies intend to scale the open data initiative globally to enrich the database, which is expected to eventually improve the inference as the sample broadens.
Wrapping Up
Microsoft’s latest initiative is a testament to the company’s growing focus on expanding presence in the multi-trillion healthcare sector with innovative solutions. Moreover, Microsoft’s ongoing healthcare initiatives in partnership with Nuance, Providence St. Joseph Health, Walgreens Boots Alliance, and UCLA, remain noteworthy.
Markedly, tech giants includingApple (AAPL - Free Report) , Alphabet, Facebook, among others, are also exploring the usage of innovative technologies including AI, Big Data and Data Science for the management of COVID-19 crisis.
For instance, Apple has unveiled a new COVID-19 section in Apple News in a bid to offer latest verified reports from trusted sources. Further, the company has taken strong measures to scrutinize the data provides by COVID-19 related apps in AppStore.
Microsoft’s expanded partnership with Adaptive is expected to aid the broader medical fraternity and the global ecosystem to advance initiatives to contain the COVID-19 spread and find a cure.
Zacks Rank
Microsoft currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Free: Zacks’ Single Best Stock Set to Double
Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, SherazMian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
See 5 Stocks Set to Double>>